A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder

@inproceedings{Wang2012ARD,
  title={A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder},
  author={Gang Wang and Alexander Mcintyre and Willie R. Earley and Shane R Raines and Hans Eriksson},
  booktitle={Neuropsychiatric disease and treatment},
  year={2012}
}
OBJECTIVES To evaluate the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). PATIENTS AND METHODS This was a 10-week (8-week active treatment/2-week post-treatment) randomized, double-blind, placebo- and active-controlled study (D1448C00004). Patients received quetiapine XR 150 mg/day, escitalopram 10 mg/day, or placebo; patients with an inadequate response (<20% improvement in Montgomery… CONTINUE READING
4
Twitter Mentions

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 35 REFERENCES

Once-daily Seroquel XR (quetiapine fumarate) extended-release tablets

AstraZeneca Pharmaceuticals
  • Available from: http://www1. astrazeneca-us.com/pi/seroquelxr.pdf. Accessed July
  • 2012
VIEW 2 EXCERPTS

and Drug Administration

US Foo
  • Antidepressant use in children, adolescents and adults. 2010. Available from: http://www.fda.gov/cder/ drug/antidepressants/default.htm. Accessed May 1,
  • 2011
VIEW 1 EXCERPT